peptide garden
Menu
News

Retatrutide's Pivotal Obesity Trial Reports at ADA 2026 — and a New Safety Signal

TRIUMPH-1, retatrutide's largest trial, delivered the strongest weight-loss data yet for the triple agonist — and surfaced a urinary tract infection signal that had not appeared in earlier trials. Updated August 15, 2026 with the TRIUMPH-2 and TRIUMPH-3 results, which measured that signal twice more.

·9 min read·Research

At the American Diabetes Association's 86th Scientific Sessions in early June 2026, Eli Lilly reported detailed results from TRIUMPH-1 — the largest and most important trial yet for retatrutide, its investigational triple GIP/GLP-1/glucagon receptor agonist.[1] The headline numbers, first released in topline form on May 21, are the strongest weight-loss data the drug has produced.[2] But the fuller dataset also surfaced something new: a urinary tract infection signal that had not appeared in earlier retatrutide trials, occurring mostly in women.

This article walks through both sides — the efficacy that has made retatrutide the most-watched obesity drug in development, and the safety details that deserve attention before anyone calls it a finished story.

Updated August 15, 2026. Two further Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, reported topline results on July 23, 2026, and they measured the same urinary tract infection signal again in two independent populations — which makes it possible to say how big it actually is. Lilly also said it plans to submit retatrutide to the FDA in the first quarter of 2027.[4]

  • Weight loss: 28.3% at 12 mg over 80 weeks (n=2,339), vs. 2.2% on placebo
  • Sustained: up to 30.3% at 104 weeks in a higher-BMI extension group
  • Sleep apnea & knee pain: large improvements in nested sub-studies
  • A signal to watch, in proportion: urinary tract infections in 7.5–8.8% (treated) vs. 5.3% (placebo) here, and 8.0% vs. 6.6% and 7.0% vs. 5.3% in the two later trials — a consistent excess of roughly 1–3 percentage points, mostly in women
  • Status: still investigational — not FDA-approved, nothing filed, and no FDA decision date exists

Quick facts

Trial name
TRIUMPH-1
Participants
2,339
Duration
80 weeks (104-week extension)
Population
Obesity/overweight, without diabetes
Doses tested
4 mg, 9 mg, 12 mg (weekly)
Design
Phase 3, double-blind, placebo-controlled
Reported
Topline May 21; ADA 2026 June 6

The efficacy story

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight plus a weight-related condition, but without type 2 diabetes. At 80 weeks, mean weight loss was dose-dependent:[2]

  • 4 mg: 19.0% (about 47 lb)
  • 9 mg: 25.9% (about 64 lb)
  • 12 mg: 28.3% (about 70 lb) vs. 2.2% (about 5 lb) on placebo

At the 12 mg dose, 45.3% of participants lost at least 30% of their body weight — a magnitude usually associated with bariatric surgery — and 65.3% reached a BMI below 30. In a pre-specified extension limited to participants who started with a BMI of 35 or higher, those who continued 12 mg reached an average of 30.3% (about 85 lb) at 104 weeks.[2]

For cross-trial context only: retatrutide's earlier TRIUMPH-4 trial showed 28.7% at 68 weeks, and semaglutide and tirzepatide have shown roughly 15% and 20–22% in their own obesity trials.[3] No head-to-head trials exist, so these comparisons are suggestive, not definitive.

Sleep apnea and knee osteoarthritis

TRIUMPH-1 embedded two "basket" sub-studies, and both reported at ADA 2026:[1]

  • Obstructive sleep apnea (n=243): the apnea–hypopnea index fell by up to 36.1 events per hour — roughly a 60% reduction from a baseline around 59 events per hour. These are the first reported retatrutide sleep-apnea efficacy data.
  • Knee osteoarthritis (n=574): WOMAC knee-pain scores improved by up to about 73%, the largest knee-OA dataset yet for the drug.

Both findings are most plausibly driven by the substantial weight loss reducing mechanical and metabolic load — and both come from topline conference data, not peer-reviewed publications.

The urinary tract infection signal, in context

The detail that drew the most new attention was a urinary tract infection (UTI) signal that had not been flagged in retatrutide's earlier trials. In TRIUMPH-1, UTIs were reported in 7.5% (4 mg), 8.8% (9 mg), and 8.4% (12 mg) of treated participants, compared with 5.3% on placebo — and they occurred predominantly in women.[1]

A few things keep this in proportion. The infections were generally mild to moderate, most resolved during continued treatment, and they rarely led anyone to stop the drug. Investigators noted the signal was new, hypothesized a possible link to hydration, and said it will be monitored as more data accumulate. A smaller, dose-dependent UTI signal also appeared in the diabetes trial TRANSCEND-T2D-1 (0.7%, 1.5%, and 2.9% across doses vs. 0% on placebo).

What the July 2026 trials added

When we first wrote this piece, the UTI numbers came from a single trial, which is exactly the situation in which a finding can look larger than it is. Two more Phase 3 trials have now measured the same thing in different populations. At the 12 mg dose, UTIs occurred in 8.0% of participants vs. 6.6% on placebo in TRIUMPH-2 (obesity with type 2 diabetes, n=1,152), and 7.0% vs. 5.3% in TRIUMPH-3 (severe obesity with established heart disease, n=1,946).[4]

Read together, the three trials tell a fairly clear story. The excess shows up every time, which suggests it is real rather than a fluke of one dataset. But the size of it is modest — roughly 1 to 3 percentage points above placebo, in populations where UTIs are already common. Put differently: if 100 women took retatrutide for a year and a half, you would expect one to three more UTIs among them than if none had. That is a real thing to know about, and worth raising with a prescriber — especially for anyone who gets UTIs often. It is not the headline risk some coverage made it out to be.

Why it matters, calmly stated: A signal that appears for the first time in a drug's largest trial is exactly the kind of finding regulators want explained before approval, and it has now been confirmed twice more. What has changed since June is the size estimate, not the direction: the events are mostly mild, mostly self-limited, and the excess over placebo is small. The safety picture is clearer than it was, and less alarming.

Dysesthesia and GI effects

ADA 2026 also gave a per-dose breakdown of dysesthesia (an altered sense of touch) in TRIUMPH-1: 5.1% (4 mg), 12.3% (9 mg), and 12.5% (12 mg), versus 0.9% on placebo.[1] That is lower than the 20.9% seen at 12 mg in TRIUMPH-4, but higher than the 2–5% reported in the diabetes trial. The July 2026 trials came in lower again — 7.3% at 12 mg in TRIUMPH-2 and 6.4% in TRIUMPH-3 — which makes TRIUMPH-4's figure look more like an outlier than the norm.[4]

Gastrointestinal side effects were consistent with the GLP-1 drug class and rose with dose, with nausea, diarrhea, and constipation the most common. Adverse-event-driven discontinuations climbed with dose, reaching 11.3% at 12 mg versus 4.9% on placebo.[2]

Where the program stands now

Two further trials reported on July 23, 2026, and both were positive.[4] TRIUMPH-2 studied 1,152 adults with obesity and type 2 diabetes, showing up to 20.8% weight loss and A1C reductions of up to 1.6 percentage points at 80 weeks. TRIUMPH-3 studied 1,946 adults with severe obesity and existing cardiovascular disease — the sickest group tested so far — and showed up to 22.6% weight loss, with large improvements in triglycerides, blood pressure, and inflammation.

Two caveats belong alongside those numbers. First, TRIUMPH-3 also had the highest rate of people stopping because of side effects anywhere in the program: 13.5% at 12 mg vs. 4.8% on placebo. Second, because TRIUMPH-3 enrolled people with heart disease, it counted cardiovascular events — and those counts do not show a benefit. Pooling the two doses, 5-point MACE came out at a hazard ratio of 0.82 (95% CI 0.55–1.22) while 3-point MACE came out at 1.12 (95% CI 0.64–1.96). Both ranges include "no effect," and the two estimates disagree with each other. This was an exploratory safety analysis in a trial not designed to answer the question. The trial that is designed to answer it, TRIUMPH-Outcomes, does not reach its primary completion date until 2029.

All four TRIUMPH readouts remain company press releases and conference presentations. None has been published in a peer-reviewed journal.

What this means for you

Retatrutide remains investigational. It is not FDA-approved, and as of August 2026 nothing has been filed. Lilly has said it plans to submit to the FDA in the first quarter of 2027 — that is a company statement about when it intends to hand in the application, not a decision date. Because no application exists, the FDA has not set a target action date, and anyone quoting one is guessing. Retatrutide is not available by prescription or from compounding pharmacies, and products sold online as "research" retatrutide are unregulated and not equivalent to a trial drug. The one other legitimate route is a narrow, physician-initiated expanded access program for people with severe, complicated obesity who have run out of approved options.

What the TRIUMPH program changes is the strength — and the texture — of the evidence. The weight-loss numbers are the highest reported for any pharmaceutical agent in obesity, they now replicate across five trials, and the sleep-apnea and knee-pain data broaden the story beyond the scale. At the same time, the UTI signal, the variable dysesthesia rates, the discontinuation figures in sicker patients, and the absence of cardiovascular outcomes are all reminders that the full picture will come into focus only with peer-reviewed publication and regulatory review.

For the complete evidence profile — mechanism, every trial, and the full safety assessment — see our retatrutide profile.

References

  1. [1]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications.” 2026. LinkConference abstract

    Eli Lilly ADA 2026 topline release (June 6, 2026) for the TRIUMPH-1 program. Source for the per-dose UTI signal, per-dose dysesthesia rates, and the nested sleep-apnea and knee-osteoarthritis basket data. Not a peer-reviewed publication.

  2. [2]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” 2026. LinkRCT

    TRIUMPH-1 topline press release (May 21, 2026). n=2,339, 80 weeks. 28.3% mean weight loss at 12 mg; 30.3% at 104 weeks in a baseline-BMI≥35 extension. Peer-reviewed publication pending.

  3. [3]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” 2025. LinkRCT

    Topline press release for TRIUMPH-4. n=445. 28.7% weight loss at 12 mg (68 weeks). Dysesthesia signal at 20.9% (12 mg).

  4. [4]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C.” 2026. LinkRCT

    Company topline press release (July 23, 2026) for TRIUMPH-2 (NCT05929079, n=1,152, obesity + type 2 diabetes) and TRIUMPH-3 (NCT05882045, n=1,946 enrolled, severe obesity + established cardiovascular disease), both at 80 weeks. Also the source for Lilly's stated plan to submit retatrutide to the FDA in Q1 2027. Neither trial has been peer-reviewed or presented at a conference.

Stay informed

Get evidence-based peptide updates. No spam, no vendor pitches — just the research and regulatory changes that matter.

Related content

Peptide

Retatrutide

Full research profile covering mechanism, all clinical trials, safety data, and evidence assessment.

News

Retatrutide's First Late-Stage Diabetes Trial

TRANSCEND-T2D-1: A1C and weight-loss results in type 2 diabetes, with much lower dysesthesia rates.

Peptide

Tirzepatide

The dual GIP/GLP-1 agonist from Eli Lilly. FDA-approved for three indications. Retatrutide's closest comparator.

Guide

Retatrutide Is Not Compoundable

Why legitimate retatrutide access is trial-only, and why research-use vendors are not equivalent.

Disclaimer

This article is for educational purposes only. Retatrutide is an investigational drug that is not FDA-approved and is not available by prescription. The trial results described are topline data from press releases and conference presentations, not peer-reviewed publications. This is not medical advice or an endorsement of retatrutide use. Always consult a licensed healthcare provider before making decisions about any medication or clinical trial participation.